Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells-Reference-Cited by-同舟云学术

Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells

Published:2010-05-12 Issue:3 Volume:12 Page:
ISSN:1465-542X
Container-title:Breast Cancer Research
language:en
Short-container-title:Breast Cancer Res

Author:

Paris Luisa,Cecchetti Serena,Spadaro Francesca,Abalsamo Laura,Lugini Luana,Pisanu Maria Elena,Iorio Egidio,Natali Pier Giorgio,Ramoni Carlo,Podo Franca

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/bcr2575.pdf

Reference70 articles.

1. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001, 2: 127-137. 10.1038/35052073.

2. Mendelsohn J, Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003, 21: 2787-2799. 10.1200/JCO.2003.01.504.

3. Lemmon MA: The EGF receptor family as therapeutic targets in breast cancer. Breast Dis. 2003, 18: 33-43.

4. Hynes NE, Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005, 5: 341-354. 10.1038/nrc1609.

5. Carlsson J, Nordgren H, Sjöström J, Wester K, Villman K, Bengtsson NO, Ostenstad B, Lundqvist H, Blomqvist C: HER2 expression in breast cancer primary tumours and corresponding metastases: original data and literature review. Br J Cancer. 2004, 90: 2344-2348.

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application and outlook of electrochemical technology in single-cell analysis;Biosensors and Bioelectronics;2023-12

2. Phosphatidylcholine-Specific Phospholipase C as a Promising Drug Target;Molecules;2023-07-25

3. Phospholipases and their metabolites in cancer;Phospholipases in Physiology and Pathology;2023

4. Mammalian phosphatidylcholine-specific phospholipase Cs;Phospholipases in Physiology and Pathology;2023

5. Targeting cancer-specific metabolic pathways for developing novel cancer therapeutics;Frontiers in Immunology;2022-12-22